A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

NCT07357766 · Not yet recruiting

Last updated 2026-05-28

This study is testing different versions of an injectable medication called CagriSema, along with a placebo, to see how they affect body weight in adults who are overweight or have obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 1,400 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-06 · est. completion 2028-01

Where 116 sites · Bulgaria, Denmark, Greece, Hungary, Malaysia, Poland, Portugal, Romania, Slovakia, South Africa, Switzerland, Taiwan, Thailand, United States

What this study is testing ClinicalTrials.gov NCT07357766 ↗

Description as written by the study sponsor.

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

Treatments tested

Cagrisema Drug

Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.
Placebo CagriSema Drug

Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07357766 ↗